| Status: Medicine does not meet criteria for AWMSG assessment | |
Product meets AWMSG exclusion criteria due to NICE appraisal ID5110: Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion-positive advanced non-small-cell lung cancer |
|
Medicine details |
|
| Medicine name | amivantamab |
| Formulation | intravenous infusion |
| Reference number | 4985 |
| Indication | In combination with carboplatin-pemetrexed chemotherapy in the first-line treatment of patients with EGFR Exon 20ins NSCLC |
| Company | Janssen-Cilag Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 17/03/2023 |
| NICE guidance | |